Methacholine

Methacholine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Turky Alkathery, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Methacholine is {{{aOrAn}}} {{{drugClass}}} that is FDA approved for the treatment of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Methacholine FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Methacholine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Methacholine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Methacholine FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Methacholine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Methacholine in pediatric patients.

Contraindications

Provocholine® (methacholine chloride powder for inhalation) is contraindicated in patients with known hypersensitivity to this drug or to other parasympathomimetic agents.

Repeated administration of Provocholine® by inhalation other than on the day that a patient undergoes challenge with increasing doses is contraindicated.

Inhalation challenge should not be performed in patients receiving any beta-adrenergic blocking agent because in such patients responses to methacholine chloride can be exaggerated or prolonged, and may not respond as readily to accepted modalities of treatment (see WARNINGS box).

Warnings

Precations

General

Administration of Provocholine® (methacholine chloride powder for inhalation) to patients with epilepsy, cardiovascular disease accompanied by bradycardia, vagotonia, peptic ulcer disease, thyroid disease, urinary tract obstruction or other condition that could be adversely affected by a cholinergic agent should be undertaken only if the physician feels benefit to the individual outweighs the potential risks.

Adverse Reactions

Clinical Trials Experience

Adverse reactions associated with 153 inhaled methacholine chloride challenges include one occurrence each of headache, throat irritation, Iightheadedness and itching.

Provocholine® (methacholine chloride powder for inhalation) is to be administered only by inhalation. When administered orally or by injection, methacholine chloride is reported to be associated with nausea and vomiting, substernal pain or pressure, hypotension,fainting and transient complete heart block. (See OVERDOSAGE.)

Postmarketing Experience

There is limited information regarding Methacholine Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Methacholine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C Animal reproduction studies have not been conducted with methacholine chloride. It is not known whether methacholine chloride can cause fetal harm when administered to a pregnant patient or affect reproductive capacity. Methacholine chloride should be given to a pregnant woman only if clearly needed.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Methacholine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Methacholine during labor and delivery.

Nursing Mothers

Provocholine® inhalation challenge should not be administered to a nursing mother since it is not known whether methacholine chloride when inhaled is excreted in breast milk.

Pediatric Use

The safety and efficacy of Provocholine® inhalation challenge have not been established in children below the age of 5 years.

Geriatic Use

There is no FDA guidance on the use of Methacholine in geriatric settings.

Gender

There is no FDA guidance on the use of Methacholine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Methacholine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Methacholine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Methacholine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Methacholine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Methacholine in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Methacholine Administration in the drug label.

Monitoring

There is limited information regarding Methacholine Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Methacholine and IV administrations.

Overdosage

Provocholine® (methacholine chloride powder for inhalation) is to be administered only by inhalation. When administered orally or by injection, overdosage with methacholine chloride can result in a syncopal reaction, with cardiac arrest and loss of consciousness. Serious toxic reactions should be treated with 0.5 mg to 1 mg of atropine sulfate, administered IM or IV.

The acute (24 hour) oral LD50 of methacholine chloride and related compounds is 1100 mg/kg in the mouse and 750 mg/kg in the rat.

Cynomolgus monkeys were exposed to a 2% (20 mg/mL) aerosol of methacholine chloride in acute (10 minute) and subchronic (7 day) inhalation toxicity studies. In the former study, animals exposed to the aerosol for up to 10 minutes demonstrated an increase in respiratory rate and decrease in tidal volume after 30 seconds. These changes peaked at 2 minutes and were followed by a rise in pulmonary resistance and a decrease in compliance. Pulmonary function returned to normal 20 to 25 minutes after exposure ended. In the 7 day study, monkeys were given daily inhalations equivalent to the maximum and roughly five times the maximum standard human dose. Although the typical pulmonary response/ recovery sequence was observed, distinct changes in airway resistance were noted at the end of the study. These changes were not rapidly reversed in the maximum equivalent standard dose group, which was observed for 9 weeks.

Pharmacology

There is limited information regarding Methacholine Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Methacholine Mechanism of Action in the drug label.

Structure

There is limited information regarding Methacholine Structure in the drug label.

Pharmacodynamics

There is limited information regarding Methacholine Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Methacholine Pharmacokinetics in the drug label.

Nonclinical Toxicology

There have been no studies with methacholine chloride that would permit an evaluation of its carcinogenic or mutagenic potential or of its effect on fertility.

Clinical Studies

There is limited information regarding Methacholine Clinical Studies in the drug label.

How Supplied

20mL amber vial containing 100mg methacholine chloride powder which is to be reconstituted with 0.9% sodium chloride injection containing 0.4% phenol (pH 7.0) – boxes of 6 (NDC 64281-100-06). • 50 mL amber vials containing 1600 mg of methacholine chloride powder which is to be reconstituted with 0.9% sodium chloride injection or with 0.9% sodium chloride injection containing 0.4% phenol (pH 7.0) – single vial per box (NDC 64281-100-16).

Storage

Store the powder at 59° to 86°F (15° to 30°C). Refrigerate the reconstituted solutions (dilutions A-D) at 36° to 46°F (2° to 8°C) for not more than 2 weeks. Dilution E must be prepared on the day of the challenge.

Images

Drug Images

{{#ask: Page Name::Methacholine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Methacholine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Methacholine Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Methacholine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Methacholine Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Methacholine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.